You just read:

PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer

News provided by

Jazz Pharmaceuticals plc

Feb 17, 2020, 02:30 ET